Y-mAbs Therapeutics (NASDAQ:YMAB) Rises 9.6% This Week, Taking One-year Gains to 161%

Yahoo FinanceApr 18 09:09 ET

Little Excitement Around Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues

With a price-to-sales (or "P/S") ratio of 7.8x Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) may be sending bullish signals at the moment, given that almost half of all the Biotechs companies in the United

Simply Wall StApr 18 06:57 ET

Y-mAbs Therapeutics Down Nearly 11%, on Pace for Largest Percent Decrease Since November 2022 -- Data Talk

Y-mAbs Therapeutics, Inc. (YMAB) is currently at $14.42, down $1.77 or 10.93% --Would be lowest close since March 18, 2024, when it closed at $13.76 --On pace for largest percent decrease since Nov.

Dow JonesApr 2 14:04 ET

Selling US$1.9m Of Stock Was Lucrative Decision For Y-mAbs Therapeutics Insiders

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) stock rose 10% last week, but insiders who sold US$1.9m worth of stock over the last year are probably in a more advantageous position. Selling at an average

Simply Wall StMar 24 10:32 ET

Y-Mabs Therapeutics CFO Resigns, Ensures Smooth Transition

TipRanksMar 14 09:33 ET

Y-mAbs Therapeutics Has Commenced a Search Process for a Successor >YMAB

Y-mAbs Therapeutics Has Commenced a Search Process for a Successor >YMAB

Dow JonesMar 14 09:06 ET